New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩85.9b market cap, or US$56.3m). Duyuru • May 22
LabGenomics Co., Ltd. announced that it has received KRW 20 billion in funding On May 20, 2026, LabGenomics Co., Ltd. has closed the transaction. Duyuru • May 13
LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in funding LabGenomics Co., Ltd. announces a private placement with Stick Litmus Co., Ltd. to issue Series 5 Unregistered Unsecured Private Convertible Bonds for gross proceeds of KRW 20,000,000,000 on May 12, 2026. Expected closing date of the transaction is May 20, 2026. Interest rate of the Notes is 0% and Maturity interest rate is 5%. Maturity date of the Notes is May 20, 2029. Notes are convertible into 13,642,564 shares at a conversion price of KRW 1,466. Conversion billing period starts from May 20, 2027 and ends on April 20, 2029. Duyuru • Feb 28
LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026 LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea New Risk • Dec 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩141.1b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩141.1b market cap, or US$96.4m). New Risk • May 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Duyuru • Feb 21
LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025 LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea New Risk • Jan 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 25% per year over the past 5 years. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). New Risk • Mar 28
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩4,050, the stock trades at a trailing P/E ratio of 72.7x. Average forward P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 9.9% over the past three years. Reported Earnings • Nov 19
Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022) Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩3,670, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 28% over the past three years. Buying Opportunity • Sep 25
Now 23% undervalued Over the last 90 days, the stock is up 35%. The fair value is estimated to be ₩6,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 4.3%. Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 9.3% over the past three years. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Shareholders have been diluted in the past year (9.2% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩9,830, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩8,200, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.6% over the past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 5.5% over the past three years. Reported Earnings • Mar 26
Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021) Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩5,480, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 3.3% over the past three years. Duyuru • Jan 19
LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in funding On January 18, 2023, LabGenomics Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 3,128,372 shares at an issue price of KRW 7,260 per share for gross proceeds of KRW 22,711,980,720. The transaction included participation from Ruha Galacticos Co., Ltd., for 3,128,372 shares. Upcoming Dividend • Dec 21
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 21 April 2023. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment improved over the past week After last week's 17% share price gain to ₩6,400, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 319% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 15% share price gain to ₩6,910, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 343% over the past three years. Valuation Update With 7 Day Price Move • Aug 25
Investor sentiment deteriorated over the past week After last week's 24% share price decline to ₩6,780, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 369% over the past three years. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 268% over the past three years. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorated over the past week After last week's 23% share price decline to ₩7,090, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 177% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 41% share price gain to ₩31,700, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 334% over the past three years. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improved over the past week After last week's 24% share price gain to ₩29,400, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 329% over the past three years. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 39x in the Biotechs industry in South Korea. Total returns to shareholders of 332% over the past three years. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improved over the past week After last week's 33% share price gain to ₩31,400, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩24,750, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 205% over the past three years. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩29,250, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 221% over the past three years. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improved over the past week After last week's 17% share price gain to ₩34,300, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 43x in the Biotechs industry in South Korea. Total returns to shareholders of 321% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 30% share price gain to ₩32,550, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 48x in the Biotechs industry in South Korea. Total returns to shareholders of 272% over the past three years. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improved over the past week After last week's 15% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 116% over the past three years. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 23% share price gain to ₩27,600, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 150% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 30% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 50x in the Biotechs industry in South Korea. Total returns to shareholders of 55% over the past three years. Is New 90 Day High Low • Feb 22
New 90-day low: ₩15,300 The company is down 33% from its price of ₩22,750 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Jan 15
New 90-day low: ₩15,850 The company is down 54% from its price of ₩34,550 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: ₩17,500 The company is down 51% from its price of ₩35,500 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: ₩20,600 The company is down 48% from its price of ₩39,850 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 10
New 90-day low: ₩27,300 The company is down 33% from its price of ₩40,800 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Oct 22
New 90-day low: ₩31,650 The company is down 22% from its price of ₩40,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.